FYB202 (biosimilar ustekinumab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for FYB202 (biosimilar ustekinumab), covering 2023-02-16 to 2023-02-16. Get the full timeline:
Most recent: Clinical Trial Update: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 3]